[HTML][HTML] SARS-CoV-2 B. 1.617 emergence and sensitivity to vaccine-elicited antibodies
Abstract The B. 1.617 variant emerged in the Indian state of Maharashtra in late 2020 and
has spread throughout India and to at least 40 countries. There have been fears that two key …
has spread throughout India and to at least 40 countries. There have been fears that two key …
[PDF][PDF] SARS-CoV-2 B. 1.617 emergence and sensitivity to vaccine-elicited antibodies
I Ferreira, R Datir, S Kemp, G Papa, P Rakshit, S Singh… - scholar.archive.org
The B. 1.617 variant emerged in the Indian state of Maharashtra in late 2020 and has spread
throughout India and to at least 40 countries. There have been fears that two key mutations …
throughout India and to at least 40 countries. There have been fears that two key mutations …
[HTML][HTML] SARS-CoV-2 B. 1.617 emergence and sensitivity to vaccine-elicited antibodies
I Ferreira, R Datir, G Papa, S Kemp, B Meng, P Rakshit… - bioRxiv, 2021 - biorxiv.org
Abstract The B. 1.617 variant emerged in the Indian state of Maharashtra in late 2020 and
has spread throughout India and to at least 40 countries. There have been fears that two key …
has spread throughout India and to at least 40 countries. There have been fears that two key …
SARS-CoV-2 B. 1.617 emergence and sensitivity to vaccine-elicited antibodies
P Mlcochova, SA Kemp, MS Dhar, G Papa, B Meng… - 2021 - pesquisa.bvsalud.org
SARS-CoV-2 B.1.617 emergence and sensitivity to vaccine-elicited antibodies | PREPRINT-BIORXIV
loading 1 2 3 +A A -A 3.SARS-CoV-2 B.1.617 emergence and sensitivity to vaccine-elicited …
loading 1 2 3 +A A -A 3.SARS-CoV-2 B.1.617 emergence and sensitivity to vaccine-elicited …
SARS-CoV-2 B. 1.617 emergence and sensitivity to vaccine-elicited antibodies
P Mlcochova, SA Kemp, MS Dhar, G Papa, B Meng… - 2021 - pesquisa.bvsalud.org
SARS-CoV-2 B.1.617 emergence and sensitivity to vaccine-elicited antibodies | PREPRINT-BIORXIV
loading 1 2 3 +A A -A 3.SARS-CoV-2 B.1.617 emergence and sensitivity to vaccine-elicited …
loading 1 2 3 +A A -A 3.SARS-CoV-2 B.1.617 emergence and sensitivity to vaccine-elicited …